Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension

Sacubitril/valsartan (LCZ696), a novel angiotensin receptor-neprilysin inhibitor, was recently approved for the treatment of heart failure with reduced ejection fraction. Neprilysin degrades several peptides that modulate lipid metabolism, including natriuretic peptides. In this study, we investigat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hypertension
Hlavní autoři: Engeli, Stefan, Stinkens, Rudi, Heise, Tim, May, Marcus, Goossens, Gijs H., Blaak, Ellen E., Havekes, Bas, Jax, Thomas, Albrecht, Diego, Pal, Parasar, Tegtbur, Uwe, Haufe, Sven, Langenickel, Thomas H., Jordan, Jens
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott, Williams & Wilkins 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5753808/
https://ncbi.nlm.nih.gov/pubmed/29180454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/HYPERTENSIONAHA.117.10224
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky